E
Eva Havrdova
Researcher at Charles University in Prague
Publications - 438
Citations - 31538
Eva Havrdova is an academic researcher from Charles University in Prague. The author has contributed to research in topics: Multiple sclerosis & Expanded Disability Status Scale. The author has an hindex of 66, co-authored 408 publications receiving 27333 citations. Previous affiliations of Eva Havrdova include University of Bologna & First Faculty of Medicine, Charles University in Prague.
Papers
More filters
Journal ArticleDOI
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
Chris H. Polman,Stephen C. Reingold,Brenda Banwell,Michel Clanet,Jeffrey A. Cohen,Massimo Filippi,Kazuo Fujihara,Eva Havrdova,Michael Hutchinson,Ludwig Kappos,Fred D. Lublin,Xavier Montalban,Paul L. O’Connor,Magnhild Sandberg-Wollheim,Alan J. Thompson,Emmanuelle Waubant,Brian G. Weinshenker,Jerry S. Wolinsky +17 more
TL;DR: These revisions simplify the McDonald Criteria, preserve their diagnostic sensitivity and specificity, address their applicability across populations, and may allow earlier diagnosis and more uniform and widespread use.
Journal ArticleDOI
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
Chris H. Polman,Eva Havrdova,Michael Hutchinson,Ludwig Kappos,David Miller,J. Theodore Phillips,Fred D. Lublin,Gavin Giovannoni,A Wajgt,Martin Toal,F Lynn,Michael Panzara,Alfred Sandrock +12 more
TL;DR: Natalizumab reduced the risk of the sustained progression of disability and the rate of clinical relapse in patients with relapsing multiple sclerosis and hold promise as an effective treatment for relapsed multiple sclerosis.
Journal ArticleDOI
Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
Robert J. Fox,David Miller,J. Theodore Phillips,Michael Hutchinson,Eva Havrdova,Mariko Kita,Minhua Yang,Kartik Raghupathi,Mark Novas,Marianne T. Sweetser,Vissia Viglietta,Katherine Dawson,Christian Sindic +12 more
TL;DR: In patients with relapsing-remitting multiple sclerosis, BG-12 (at both doses) and glatiramer acetate significantly reduced relapse rates and improved neuroradiologic outcomes relative to placebo.
Journal ArticleDOI
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.
Jeffrey A. Cohen,Alasdair Coles,Douglas L. Arnold,Christian Confavreux,Edward Fox,Hans-Peter Hartung,Eva Havrdova,Krzysztof Selmaj,Howard L. Weiner,Elizabeth Fisher,Vesna V. Brinar,Gavin Giovannoni,Miroslav Stojanovic,Bella Ertik,Stephen Lake,David Margolin,Michael Panzara,D Alastair S Compston +17 more
TL;DR: Alemtuzumab's consistent safety profile and benefit in terms of reductions of relapse support its use for patients with previously untreated relapsing-remitting multiple sclerosis; however, benefit interms of disability endpoints noted in previous trials was not observed here.
Journal ArticleDOI
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: A randomised controlled phase 3 trial
Alasdair Coles,Cary Twyman,Douglas L. Arnold,Jeffrey A. Cohen,Christian Confavreux,Edward Fox,Hans Peter Hartung,Eva Havrdova,Krzysztof Selmaj,Howard L. Weiner,Tamara Miller,Elizabeth Fisher,Rupert Sandbrink,Rupert Sandbrink,Stephen Lake,David Margolin,Pedro Oyuela,Michael Panzara,D Alastair S Compston +18 more
TL;DR: This 2 year, rater-masked, randomised controlled phase 3 trial enrolled adults aged 18-55 years with relapsing-remitting multiple sclerosis and at least one relapse on interferon beta or glatiramer and found alemtuzumab could be used to reduce relapse rates and sustained accumulation of disability.